ResMed Inc. (RMD)

FairStock Score: 72/100 — STEADY

Key Financials

Strengths

• Exceptional profitability: 27.59% net margin in latest quarter with consistent 25.68% ROE
• Strong free cash flow generation: $1.4B annually supporting reinvestment and shareholder returns
• Durable moat in essential healthcare: Recurring revenue from both respiratory devices and software platforms with aging population tailwinds
• Fortress balance sheet: 0.13 debt-to-equity ratio provides financial flexibility
• High-quality operations: Piotroski F-Score of 8/9 indicates strong financial fundamentals and earnings quality

Concerns

• Severe valuation premium: 63x EV/EBITDA and trading at nearly 5x Graham Number with -382% margin of safety
• Minimal valuation cushion: 0.9% FCF yield and 22.38 P/E offer no protection against disappointment
• Valuation-dependent returns: Future gains require either multiple expansion or exceptional growth in mature healthcare markets
• Beta of 0.89 masks concentration risk: Premium valuation leaves little room for error or competitive disruption

AI Analysis

ResMed presents a classic quality company at a premium price—a situation I've learned to approach with caution. The business itself is excellent: 27.6% net margins in Q4, a 25.68% ROE, and $1.4B in free cash flow demonstrate genuine competitive strength in respiratory care and software solutions. The company enjoys recurring revenue from both device sales and cloud-based software, creating a durable moat in an essential healthcare sector with aging demographics as tailwinds. However, I cannot ignore the valuation reality. At $247, ResMed trades at 63x EV/EBITDA—a multiple typically reserved for high-growth technology companies. The Graham Number of $51.25 suggests the stock is priced at nearly 5x intrinsic value with a negative margin of safety of -382%. Even with a 0.13 debt-to-equity ratio and fortress-like balance sheet, paying this premium requires assuming perpetual growth and execution that few companies sustain. The Piotroski F-Score of 8/9 and Altman Z-Score of 11.73 indicate solid financial health, not distress. But quality alone doesn't justify valuation. At $200, I'd view this differently. At $247, I'm reminded of my principle: it's far better to buy a wonderful company at a fair price than a fair company at a wonderful price. ResMed is the former at the latter price. The 0.9% FCF yield and 22.38 P/E further confirm we're paying for perfection. Growth must accelerate meaningfully and multiples must expand further to justify current levels—unlikely in mature healthcare markets.

Bull Case

ResMed's exposure to digital health transformation and remote patient monitoring positions it to grow faster than historical rates, potentially justifying higher multiples. Strong margins and cash generation could fund strategic acquisitions that accelerate growth while the aging global population ensures decades of tailwind for respiratory care.

Bear Case

Economic pressure could reduce healthcare spending and device utilization, while competitive pressures and reimbursement headwinds could compress margins. At current valuations, even modest deceleration triggers significant downside as the multiple reverts to more reasonable levels.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer